Abstract
CD4pos T-cell subsets play a role in myelodysplastic syndromes (MDS) pathogenesis and may be affected upon 5-azacitidine (Aza) treatment. Aza enhanced human TH1 frequencies in vitro but not in vivo. The proportion of functional FoxP3pos regulatory T cells (Treg) was enhanced by Aza in vitro (p<0.0002), and a modest, temporary increase was observed in vivo (p=0.08). The overall number of TH17 was reduced both in vitro (p<0.03) and in vivo (p<0.006), indicating that Aza directly affects CD4pos polarization during activation in vitro. Upon in vivo treatment in high risk MDS patients, particularly the TH17-Treg axis is affected.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
